[Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
Octreotide, as well as endogenous somatostatin, inhibits GH and TSH secretion. The drug is employed in the medical therapy of acromegaly. We studied the effects of a long-term (1-120 months; median 12 months) therapy with octreotide (300 micrograms/day) given in 3-times intermittent s.c. administration or in pulsatile s.c. (25 micrograms/120 min) way, upon the pituitary-thyroid axis. Thirteen patients (11 with normal thyroid function, 1 with secondary hypothyroidism, 1 with toxic goiter) with active acromegaly were studied. In the euthyroid patients no significative variations in both TSH levels and thyroid hormones were found during octreotide therapy. In the non-euthyroid patients octreotide did not induce changes in the dosages of drugs acting to thyroid function. The 24-hour IC-TSH levels did not show any variation during octreotide. TSH response to TRH was reduced (P < 0.05) during octreotide therapy. No correlation among TSH, IGF-I and GH levels was observed. Long-term treatment of acromegaly with octreotide reduces TSH response to TRH but do not interfere with both 24-hour IC-TSH levels and thyroid function.
Cuttica
C M
CM
DISEM, Cattedra di Endocrinologia, Università, Genova.
Fazzuoli
L
L
Cariola
G
G
Carraro
A
A
Porcella
E
E
Giusti
M
M
Giordano
G
G
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology; D013961:Thyroid Gland / Q000187:drug effects / Q000502:physiology; D013963:Thyroid Hormones / Q000097:blood; D013972:Thyrotropin / Q000097:blood / Q000187:drug effects; D013997:Time Factors
D013963:Thyroid Hormones; D013972:Thyrotropin; D013006:Growth Hormone; D015282:Octreotide
Comportamento dell'asse ipofiso-tiroideo in soggetti acromegalici durante prolungato trattamento intermittente e pulsatile con octreotide.